REG - ABCAM Plc - Director/PDMR Shareholding
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100428:nRSb9768Ka
RNS Number : 9768K
ABCAM Plc
28 April 2010
For immediate release 28 April 2010
ABCAM PLC
("Abcam" or "the Company")
Director and PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, has today been notified that Jane Cooke, a PDMR of the Company, sold 5000 ordinary shares of 1 pence each in the
Company at 1195p per share on 27 April 2010 and also sold a further 4029 ordinary shares of 1 pence each at 1163.47p per
share on 28 April 2010.
The Company has also been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to
the benefit of the Directors and PDMRs:
Name Partnership Shares purchased on 26 April 2010 at 1216.95 pence per share Matching Sharesawarded on26 April 2010 at 1216.95 pence per share Dividend Shares purchased on 26 April 2010 at 1215.95 pence per share Subsequent Beneficial Interest in the Company Subsequent percentage holding of the Company's issued share capital
Mark Bushfield 10 10 2 85 0.0002%
Philippe Cotrel 11 11 7 361 0.001%
Jane Cooke - - 8 530 0.001%
Jonathan Milner - - 8 5,739,031 15.96%
Jim Warwick - - 8 580,060 1.61%
Jeff Iliffe - - 8 500 0.001%
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award
subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their
release.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news